Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
CareStream

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 10 December 1999:
Vol. 286. no. 5447, p. 2063
DOI: 10.1126/science.286.5447.2063
Prev | Table of Contents | Next

News Focus

SWEDEN:
Drug Research Endures the Pains of Globalization

Joanna Rose and Annika Nilsson

STOCKHOLM--Sweden's drug companies have joined the transnational drug industry, but their researchers are finding the global job market tough going. In 1995, Pharmacia merged with U.S.-based drug giant Upjohn, and since then the new company has cut its R&D personnel in Sweden by one-third, from 1500 to 1000. Last spring, Astra merged with Britain's Zeneca, and last week, the seemingly inevitable job cuts were announced: AstraZeneca plans to cut 450 positions from its research staff of 4000 in Sweden.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)